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 1 
Abstract 2 
 3 
Although bacteria are generally regarded as the causative agents of infectious diseases, 4 
most bacteria inhabiting the human body are non-pathogenic and some of them can be 5 
turned, after proper engineering, into “smart” living therapeutics of defined properties 6 
for the treatment of different illnesses. This review focuses on recent developments to 7 
engineer bacteria for the treatment of diverse human pathologies, including 8 
inflammatory bowel diseases, autoimmune disorders, cancer, metabolic diseases and 9 
obesity, as well as to combat bacterial and viral infections. We discuss significant 10 
advances provided by synthetic biology to fully reprogram bacteria as human 11 
therapeutics, including novel measures for strict biocontainment. 12 13 
Graphical abstract (for review)
 3 
Introduction 1 
Bacteria are key elements for human health. Two evidences support this notion, the 2 
existence of a stably population of microbes, termed microbiota, in healthy individuals 3 
and the number of health disorders associated to axenic (germ-free) animals [1,2]. In 4 
addition, bacteria have been actively administered in patients suffering from different 5 
illnesses for over a century. These intentional administrations are in general carried out 6 
with natural isolates obtained from the microbiota of healthy individuals and are 7 
referred to as probiotics. In most cases they belong to lactic acid bacteria (LAB) and in 8 
a lesser extent to Escherichia coli strains [3]. The development of efficient DNA 9 
technologies for manipulation of microbial genomes and the increasing knowledge of 10 
the molecular basis of diseases are allowing the engineering of tailored bacteria for the 11 
treatment of human disorders.  Bacteria can be altered to produce a continuous and 12 
inexpensive supply of heterologous molecules of biomedical interest, such as human 13 
hormones, interleukins (ILs) and antibodies (Abs) within specific organs or tissues. We 14 
have restricted this review to bacterial engineering for human therapies, but similar 15 
concepts can be applied for the development of live bacterial vaccines [4]. 16 
 17 
Engineered bacteria against inflammatory and autoimmune disorders 18 
Inflammatory bowel diseases (IBDs) have been prototypical targets of probiotic 19 
therapies, given the immunomodulatory effects that certain strains are able to exert in 20 
the gastrointestinal tract (GIT). Patients suffering from IBDs frequently have alterations 21 
in pattern recognition receptors and pro-inflammatory genes, which elicit an abnormal 22 
activation of the immune system in the gut and lead to chronic intestinal inflammation 23 
and to an increased rate of oxidative stress [5]. Different bacteria, mostly LAB, have 24 
been engineered to express a wide variety of compounds in situ (i.e. anti-inflammatory 25 
cytokines, anti-oxidant enzymes) to prevent the appearance of these symptoms [6].  26 
These strategies are summarized in Figure 1. At least three of these engineered 27 
microorganisms have been tested in clinical trials. A Lactococcus lactis strain, 28 
engineered to secrete the anti-inflammatory cytokine IL-10 [7] showed a clinical benefit 29 
 4 
in 8 out of 10 patients tested with Crohn's disease [8], probably by inducing regulatory 1 
T cells (Tregs) through activation of dendritic cells (DCs) [9]. Another approach 2 
involved the use of engineered L. lactis strain secreting single domain antibody 3 
fragments (nanobodies) [10] against the pro-inflammatory cytokine Tumor Necrosis 4 
Factor alphaTNF-D . This study showed promising results in murine models of IBD 5 
[11] and the bacterial strain has been tested in a phase 1 clinical trial by Actogenix 6 
(http://www.actogenix.com/). Lastly, L. lactis expressing human Trefoil Factor 1 7 
(hTFF1) - a cytopeptide involved in epithelial wound healing - has been formulated as a 8 
mouthwash for the treatment of oral mucositis [12], which is a common complication 9 
found in patients that are subjected to chemo- and radiotherapies. This therapy has 10 
already passed through a phase 1 pharmacokinetic study and a phase 1b clinical trial 11 
involving cancer patients receiving chemotherapy, which showed alleviation of 12 
ulcerative oral mucositis symptoms in 30% of cases [13].  13 
 14 
Besides the treatment of IBDs, engineered LAB secreting specific peptide antigens have 15 
been delivered orally to induce mucosal immune tolerance to antigens involved in food-16 
allergies (e.g. ovalbumin) [14] or to gliadin antigens in the celiac disease [15]. 17 
Interestingly, this approach has been also applied to treat type 1 diabetes (T1D), an 18 
autoimmune disorder that arises from insufficient tolerance to self-antigens of 19 
pancreatic E-cells. An engineered L. lactis strain secreting the auto-antigen proinsulin 20 
and the anti-inflammatory cytokine IL-10, combined with subtherapeutic doses of 21 
systemic anti-CD3 Abs, was administered to non-obese diabetic (NOD) mice [16]. The 22 
immunosuppressive effect of anti-CD3 Abs (targeting the T-cell receptor) hampers 23 
immune system activation, whereas IL-10 avoids inflammation in the gastrointestinal 24 
mucosa and induces the development of Tregs, providing altogether an ideal scenario 25 
for the induction of tolerance.  After 6 weeks of daily oral administration of the 26 
engineered strain, approximately 60% of the mice stably reverted diabetes, probably as 27 
a consequence of the infiltration of Tregs into pancreatic islets. Responding mice 28 
showed normal glucose levels in blood, and remained responsive to other antigens, 29 
 5 
suggesting an antigen-specific immunosuppression. A similar combination therapy 1 
based on anti-CD3 Abs and the oral delivery of engineered L. lactis secreting IL-10 and 2 
the diabetes-related auto-antigen glutamic acid decarboxylase (GAD)-65 has been 3 
reported [17].  This combination was effective in the treatment of advanced stages of 4 
T1D with severe hyperglycemia. Induction of tolerance against heat shock proteins 5 
(HSPs) has been also achieved using LAB. HSPs partipate in the control of 6 
autoimmunity and in the cellular response to stress and are overexpressed in diseases 7 
involving inflammation and autoimmunity mechanisms, such as atherosclerosis and 8 
encephalomyelitis [18]. Oral administration of L. lactis strains secreting different forms 9 
of HSP-65 exerted a protective effect against endothelial damage and against the 10 
formation of atherosclerotic lesions in a low-density lipoprotein receptor-deficient 11 
(LDL-RD) mouse model [19]. This approach also prevented the development of 12 
encephalomyelitis in mice, showing reduced inflammatory cell infiltrate in the spinal 13 
cord [20]. These effects were associated with increased production of IL-10 and reduced 14 
levels of IL-17 and interferon gamma (IFN-J). 15 
 16 
Engineered bacteria against cancer 17 
Firsts reports of bacterial treatments against solid tumors date from the end of the 19th 18 
century. Over the years many genera of (facultative and strict) anaerobic bacteria (e.g. 19 
Salmonella, E. coli, Clostridium, Bifidobacterium) were reported to proliferate 20 
preferentially within solid tumors [21] due to a combination of mechanisms. These 21 
include enhanced bacterial entry and retention in tumors caused by their chaotic and 22 
leaky vasculature [22,23] and unimpeded bacterial replication in the anoxic and 23 
immune-deficient tumor microenvironment, which lacks macrophage and neutrophil 24 
clearance mechanisms [24]. Chemotaxis and active motility of bacteria has also been 25 
shown to have a positive influence in the colonization of tumors [25,26]. Intra-vesicle 26 
administration of Bacillus Calmétte-Guerin (BCG) has been used in the clinic during 27 
the last decades as the standard treatment for high-grade non-muscle invasive bladder 28 
cancer [27], representing a good example of a current anti-cancer therapy in which 29 
 6 
bacteria is employed to stimulate the immune system  in order to promote the killing of  1 
cancer cells by a mechanism that is not yet fully understood. 2 
 3 
Bacteria can bypass problems associated with poor selectivity and limited tumor 4 
penetrability of conventional cancer chemotherapies, and can be finely engineered to 5 
sense and respond to the tumor microenvironment [28]. However, the antitumoral effect 6 
of bacterial growth within tumors is generally weak, and different strategies have been 7 
followed to improve their therapeutic potential against cancer. One of them is the direct 8 
destruction of tumor cells through the secretion of bacterial toxins in situ (e.g. 9 
Staphylococcus aureus alpha hemolysin) [29,30] or the expression of pro-drug 10 
converting enzymes that locally convert non-toxic prodrugs into drugs, like E. coli 11 
cytosine deaminase (CD) that transforms non-toxic prodrug 5-Fluorocytosine into toxic 12 
5-Fluorouracil, resulting in a bacterial-directed enzyme prodrug therapy (BDEPT) 13 
localized in tumor areas [31]. BDEPT provides an excellent tumor selectivity since the 14 
drug is produced in situ, however, and similarly to conventional chemotherapy, its 15 
efficiency is highly dependent on physico-chemical properties of the prodrug that will 16 
define its ability to reach deep areas of the tumor in which bacteria (and therefore the 17 
converting enzyme) are located. In another strategy, engineered bacteria compete with 18 
the mechanisms that foster tumor formation (i.e. angiogenesis, resistance to apoptosis, 19 
evasion from the immune system, etc.) through the in situ delivery of polypeptides with 20 
pro-apoptotic activity (e.g. TNF-related apoptosis-inducing ligand -TRAIL-, Fas ligand, 21 
Noxa), anti-angiogenic factors (e.g. Endostatin, Thrombospondin 1), and cytokines (e.g. 22 
IL-2, LIGHT) that induce the immune system against tumor cells [28,32]. These 23 
strategies are shown in Figure 2. Interestingly, an additional level of specificity is 24 
provided by controlled gene expression with promoters that specifically respond to 25 
small chemical inducers (e.g. L-arabinose, anhydrotetracycline, salicylate) [33,34], 26 
tumor environment [35], hypoxia [36], or J-irradiation [37]. Remarkably, the expression 27 
of the desired therapeutic protein can be specifically triggered within tumors using 28 
bacterial promoters responding to quorum sensing molecules released by the high-29 
 7 
density of bacteria in tumors [38]. A similar strategy has also been employed to amplify 1 
the expression of the desired protein induced with small molecules (e.g. L-arabinose) 2 
that diffuse poorly within the tumor mass [39]. Bacteria have also been engineered to 3 
silence the expression of important genes related to tumor development through RNA 4 
interference. For instance, E. coli was engineered to transfer to host cells plasmids 5 
encoding short-hairpin RNAs (shRNAs) silencing beta-1, whose 6 
overexpression is involved in several types of cancer [40]. This therapy has been 7 
granted by the FDA as orphan drug for the treatment of familial adenomatous polyposis 8 
and Marina Biotech (http://www.marinabio.com/) is currently developing clinical trials 9 
to analyze the safety and tolerability of its oral administration. 10 
 11 
First reported clinical trials with refractory cancer patients using systemic 12 
administration of engineered Salmonella strains highlighted the trade-off between safe 13 
and effective dose, since the highest tolerated dose was insufficient for effective tumor 14 
colonization [41]. Hence, improving bacterial tumor colonization at low bacterial doses 15 
is an area of great interest. A promising advance is the constitutive and non-toxic 16 
expression on the bacterial surface of synthetic adhesins, which contain nanobodies 17 
targeting antigens expressed on the surface of tumor cells [42].  Expression of synthetic 18 
adhesins in E. coli allowed a significant reduction of two-orders of magnitude in the 19 
dose of bacteria needed for efficient colonization of target solid tumors in mice. 20 
 21 
Engineered bacteria for the treatment of metabolic disorders 22 
Given that the intestinal microbiota influences the susceptibility of an individual to 23 
develop metabolic disorders, it seems reasonable that the introduction of properly 24 
engineered bacteria could ameliorate their symptoms. In the case of obesity it has been 25 
demonstrated that the composition of the microbiota in lean mice is different from the 26 
one found in obese mice [43,44]. Furthermore, experiments involving transplantation of 27 
the intestinal microbiota from human identical twins discordant for obesity to germ-free 28 
mice revealed that only those mice receiving microbiota from the obese human 29 
 8 
developed obesity [45]. Recently, an approach to control obesity has been developed 1 
based on an engineered E. coli Nissle 1917 (EcN) strain expressing an N-acyltransferase 2 
from Arabidopsis thaliana that synthesizes N-acylphosphatidylethanolamines (NAPEs) 3 
[46]. NAPEs are precursors of the N-acylethanolamide (NAE) family of lipids, which 4 
are naturally synthesized in the small intestine in response to feeding and cause a 5 
reduction in food intake and obesity. Incorporation of NAPE-expressing EcN in 6 
drinking water diminished food intake in mice, reducing body fat and weight gain, with 7 
no signs of adverse effects due to bacterial administration. Treated mice also had lower 8 
levels in plasma of insulin and leptin. Interestingly, the protective effect of the 9 
engineered bacteria persisted for at least 4 weeks after their removal from drinking 10 
water, suggesting a non-transient colonization of the GIT. 11 
 12 
Engineered bacteria have been also administered to lower the elevated blood glucose 13 
levels (hyperglycemia) in T1D. The gut hormone Glucagon-like peptide (GLP)-1 was 14 
known to induce insulin production in epithelial cells [47]. An engineered Lactobacillus 15 
gasseri strain secreting GLP-1 has been able to reprogram intestinal cells into insulin-16 
secreting cells [48]. Reprogrammed rat intestinal epithelia expressed important markers 17 
of pancreatic E cells, and the insulin secretion kinetics were similar to those of healthy 18 
control rats, indicating that insulin production was glucose-responsive. 19 
 20 
Engineered bacteria to combat viral and bacterial infections 21 
Intervention against viral and bacterial infections has been addressed with engineered 22 
bacteria, which have been recently reviewed [49]. A wide variety of approaches have 23 
been followed, including binding of toxins, interference with quorum sensing molecules 24 
and adhesion mechanisms, release of neutralizing antibodies and antimicrobial factors, 25 
which are summarized in Figure 3. For instance, an engineered Streptococcus mutans 26 
strain deficient for lactic acid production - therefore unable to produce dental caries  - 27 
and secreting a bacteriocin capable of killing virtually all other streptococci strains, was 28 
shown to displace cariogenic S. mutans in a rat model [50]. More recently, strains of L. 29 
 9 
lactis [51] and E. coli [52] have been engineered to secrete different bacteriocines in 1 
response to multiresistant Enterococcus faecalis pheromones and Pseudomonas 2 
aeruginosa quorum sensing molecules, respectively, showing bactericidal activity in 3 
vitro. Furthermore, an engineered Lactobacillus casei strain secreting human lactoferrin 4 
was demonstrated as effective to reduce the load of pathogenic E. coli in the duodenal 5 
fluid of infected mice, thus improving their illness score compared with untreated mice 6 
[53]. Production of antiviral molecules by engineered bacteria has been also 7 
investigated. Lactobacillus jensenii, a microorganism that is part of normal flora in 8 
human vagina, was engineered to secrete cyanovirin-N, a cyanobacterial protein with 9 
antiviral activity against HIV. Notably, trials in Rhesus macaques treated with the 10 
engineered L. jensenii strain and later challenged with simian HIV, showed a 63% 11 
reduction in HIV infection [54]. Modified Lactobacillus strains have been also used to 12 
deliver nanobodies interfering with rotavirus infection [55]. Lastly, there is a recognized 13 
potential in the incorporation of engineered bacteria into the microbiota of vector insects 14 
that mediate the transmission of human pathogens such as Trypanosoma cruzi, the 15 
causative agent of Chagas disease [56].  16 
 17 
Stem cell reprogramming and genome edition using engineered bacteria 18 
Although new technologies for genome edition such as transcription activator-like 19 
effector nucleases (TALENs) and clustered regulatory interspaced short palindromic 20 
repeat (CRISPR)/Cas9 endonuclease, are minimizing the risk of undesired genome 21 
modifications [57], reprogrammed stem cells obtained through DNA transfer techniques 22 
have a limited clinical applicability due to the risk of insertional mutagenesis during the 23 
differentiation process. In addition, it has been reported that successfully reprogrammed 24 
induced pluripotent stem cells (iPSCs) show a pronounced silencing of the transgenes 25 
encoding for reprogramming factors, suggesting that these factors are required only 26 
transiently to mediate cell reprogramming [58]. Transient protein delivery represents a 27 
good alternative to mediate differentiation of stem cells, since completely avoids the 28 
risk of insertional mutagenesis and provides a measure for the temporal control of cell 29 
 10 
exposure to reprogramming factors. The Type III Secretion System (T3SS) found in 1 
different Gram-negative pathogenic strains (Salmonella, Shigella, Yersinia, E. coli) is a 2 
needle-like macromolecular complex on the bacterial cell envelope that directly 3 
translocates effector proteins into the cytoplasm of infected host cells [59]. Attenuated 4 
strains carrying a functional T3SS have been used to deliver vaccine polypeptides and 5 
proteins of therapeutic potential (e.g. antibodies) into mammalian cells [60,61]. Bacteria 6 
with T3SS have also been employed to deliver enzymes and transcription factors that 7 
can edit the mammalian genome and reprogram cell differentiation. An attenuated strain 8 
of Pseudomonas aeruginosa harboring a functional T3SS has been shown to deliver 9 
Cre-recombinase into the nucleus of mouse embryonic stem cells (or iPS) [62] 10 
triggering loxP mediated excision of the nuclear reprogramming cassette carrying c-11 
Myc, Klf4, Oct4 and Sox2 [63]. The T3SS of this bacterial strain has also been used to 12 
translocate TALENs into human cells, which are capable of genome edition [64]. The 13 
same group reported the differentiation of mouse embryonic fibroblasts into myocites 14 
through the T3SS-mediated injection of MyoD, a transcription factor that acts as master 15 
regulator of myogenesis [65].  16 
 17 
Synthetic Biology approaches improving bacterial therapies  18 
Synthetic biology aims to rationally design bacteria for therapy and other applications 19 
through the development of computational tools and techniques for extreme genetic 20 
manipulation. By these means, designed biological modules, devices and regulatory 21 
circuits of predictable behavior can be integrated into a bacterial chassis genome with 22 
strict biocontainment measures [66]. In recent years there have been multiple reports 23 
describing modular parts and more complex devices that can be used to program 24 
important aspects of the designed bacteria: controlled expression of payload proteins 25 
[67,68], programmable adhesion to target surfaces and cells [42], or the incorporation of 26 
stable memory into the engineered bacteria [69,70] that can be used to detect small 27 
molecules in the gut [71]. Programming of bacterial tropism has also been demonstrated 28 
by engineering E. coli chemotaxis toward areas in which a pathogen, such as P. 29 
 11 
aeruginosa, is present [72]. Recent advances in engineering chemoreceptors and 1 
chemoeffectors [73] may allow a programmable chemotaxis to other molecules of 2 
interest in the future.   3 
 4 
Ideal engineered bacteria for therapy should be sensitive to antibiotics and be free of 5 
mobile elements such as transposons and plasmids. Stable integration of the 6 
recombinant DNA in the chromosome is the simplest way to minimize gene flow, but 7 
there are other strategies available, like a mutually dependent host-plasmid platform 8 
based on conditional origins of replication, auxotrophies and toxin anti-toxin pairs [74]. 9 
In addition, engineered bacteria must have own containment strategies resistant to 10 
environmental supplementation, mutagenic drift and horizontal gene transfer. All these 11 
safeguards should avoid the spreading of these microorganisms into the environment 12 
and the proliferation of deleterious bacteria.  Classically, biocontainment has been 13 
achieved through either engineered auxotrophies (e.g. strains deficient for thymidylate 14 
synthase) or induced lethality, which have been applied in clinical trials [8,13]. 15 
Synthetic biology is providing stricter biocontainment of the engineered bacteria. 16 
Minimal genomes encoding only the genes needed to sustain life might preclude 17 
unexpected evolution of engineered microbes. These minimal genomes could be 18 
generated through genome reduction techniques [75] and provide an excellent genetic 19 
chassis to implement the designed therapeutic gene devices (Fig. 4). However, the 20 
definitive firewall for biocontainment might be the use of artificial genetic languages. 21 
Indeed, there are already available engineered E. coli strains that either incorporate a 22 
non-standard amino-acid in the core of essential proteins [76] or the synthetic thymine 23 
analogue 5-chlorouracil instead of the natural thymine nucleotide in the DNA [77]. 24 
These strains exhibit strong resistance to evolutionary escape through mutagenesis or 25 
horizontal gene transfer, and cannot be supplemented with natural compounds.  26 
 27 
Concluding remarks 28 
Engineered bacteria represent an effective method to deliver therapeutic molecules in 29 
 12 
vivo allowing the development of novel treatments against infections and major human 1 
diseases such as inflammatory, autoimmune and metabolic disorders, and cancer. In 2 
addition, engineered bacteria could help to reprogram host cells by delivering 3 
transcription factors and enzymes for genome modification. Next-generation therapeutic 4 
applications of bacteria will be based on the conscious design of microorganisms with 5 
defined properties for specific applications, rather than on the finding of probiotic 6 
isolates. This fine engineering can complement a genetic bacterial chassis with modules 7 
and parts designed de novo or based on the engineering of the plethora of devices that 8 
bacteria have evolved to interact with human cells, such as immuno-modulatory and 9 
effector proteins, chemotactic sensor systems, adhesins and protein delivery 10 
machineries. Human origins are those of nomad hunters and fruit pickers that flourished 11 
when they learned how to breed and cross wild animals and plants into the variants that 12 
still feed ourselves today. Similarly, microbiology started from microbe hunters 13 
studying wild bacteria and is now evolving to the rationale design of safe engineered 14 
bacteria able to monitor our bodies and fight against human diseases. 15 
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Figure Legends 1 
 2 
Figure 1. Engineered bacteria against inflammatory disorders. Scheme depicting 3 
major strategies followed against inflammatory disorders in the gastrointestinal tract.  4 
Bacteria (green) can release locally antibody fragments (brown Ys) against pro-5 
inflammatory cytokines (red dots), anti-oxidant enzymes (yellow dots), or anti-6 
inflammatory cytokines (blue dots) acting on lymphocytes, and other cells of the 7 
mucosal immune system.  8 
 9 
Figure 2. Engineered bacteria in cancer therapies. Scheme showing common 10 
approaches in bacterial interventions against tumors. Bacteria preferentially accumulate 11 
and replicate within solid tumors allowing localized expression of reporter genes, 12 
bacterial toxins, pro-drug converting enzymes, pro-apoptotic molecules and cytokines. 13 
In addition, bacteria can harbor plasmids that, once transferred into cancer cells, may 14 
encode shRNAs for gene silencing.  15 
 16 
Figure 3. Strategies to combat infections with engineered bacteria. A pathogenic 17 
bacterium is represented in the center releasing toxins (red molecules) and quorum 18 
sensing signals (orange molecules) to the medium and expressing surface adhesins 19 
(light blue lines). Engineered bacteria (brown) over the microvilli of host cells (yellow) 20 
show different strategies against the pathogen: (A) Toxin neutralization using modified 21 
surface components.  (B) Production of antimicrobial factors (green molecules) upon 22 
detection of quorum sensing signals from the pathogen mediating killing of pathogenic 23 
bacteria. (C) Interference with quorum sensing mechanisms by the release of alternative 24 
quorum sensing signals (grey molecules) triggering repression of virulence genes. (D) 25 
 21 
Prevention of colonization. Bacteria can be engineered to secrete antibodies and adhesin 1 
subunits that competitively inhibit pathogen adhesion to host cells.  2 
 3 
Figure 4. Synthetic bacteria for biomedical applications. Scheme of an engineered 4 
bacterium based on a minimal chassis (grey) carrying diverse genetic modules of 5 
interest for therapy. A chemotactic module (light blue) could control bacterial migration 6 
in response to environmental signals of interest (orange molecules). A sensory module 7 
(purple) could detect environmental signals and respond by activating the transcription 8 
of a payload (yellow) and/or reporter (orange) modules. An adhesion module (green) 9 
could facilitate binding of the engineered bacteria to a specific target cell or tissue. A 10 
delivery module (pink) may allow the release of therapeutic molecules. A containment 11 
module (red) prevents the environmental spread of the synthetic bacterium. 12 
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